Portal de Periódicos da CAPES

Atypical fibroxanthoma versus benign and malignant fibrous histiocytoma. A comparative study of their proliferative activity using MIB-1, DNA flow cytometry, and p53 immunostaining

1995; Wiley; Volume: 75; Issue: 5 Linguagem: Inglês

10.1002/1097-0142(19950301)75

1097-0142

Yumi Oshiro, Toshiro Fukuda, Masazumi Tsuneyoshi,

Oral and Maxillofacial Pathology

CancerVolume 75, Issue 5 p. 1128-1134 Original ArticleFree Access Atypical fibroxanthoma versus benign and malignant fibrous histiocytoma. A comparative study of their proliferative activity using MIB-1, DNA flow cytometry, and p53 immunostaining Yumi Oshiro M.D., Yumi Oshiro M.D. Second Department of Pathology, Faculty of Medicine, Kyushu University 60, Fukuoka, JapanSearch for more papers by this authorToshiro Fukuda M.D., Toshiro Fukuda M.D. School of Health Science, Kyushu University 60, Fukuoka, JapanSearch for more papers by this authorMasazumi Tsuneyoshi M.D., Corresponding Author Masazumi Tsuneyoshi M.D. Second Department of Pathology, Faculty of Medicine, Kyushu University 60, Fukuoka, JapanSecond Department of Pathology, Faculty of Medicine, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka 812, Japan===Search for more papers by this author Yumi Oshiro M.D., Yumi Oshiro M.D. Second Department of Pathology, Faculty of Medicine, Kyushu University 60, Fukuoka, JapanSearch for more papers by this authorToshiro Fukuda M.D., Toshiro Fukuda M.D. School of Health Science, Kyushu University 60, Fukuoka, JapanSearch for more papers by this authorMasazumi Tsuneyoshi M.D., Corresponding Author Masazumi Tsuneyoshi M.D. Second Department of Pathology, Faculty of Medicine, Kyushu University 60, Fukuoka, JapanSecond Department of Pathology, Faculty of Medicine, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka 812, Japan===Search for more papers by this author First published: 1 March 1995 https://doi.org/10.1002/1097-0142(19950301)75:5 3.0.CO;2-HCitations: 34AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract Background. MIB-1 was found to be detectable in formalin fixed, paraffin embedded materials with microwave treatment using Ki-67 monoclonal antibody, and immunostaining has been widely documented as a useful marker of proliferation. Because atypical fibroxanthoma (AFX) is regarded as a fibrohistiocytic tumor with an intermediate potential, the proliferative activity of AFX was compared with that of benign and malignant fibrous histiocytomas. Methods. Thirty-eight soft tissue tumors including atypical fibroxanthoma (n = 5), benign fibrous histiocytoma (FH) (n = 17) and malignant fibrous histiocytoma (MFH) (n = 16) were examined using immunohistochemistry to determine MIB-1, DNA flow cytometry, and p53 (PAb 1801) immunostaining. Results. The mean of the MIB-1 labeling index (MIB-1 LI), defined as the percentage of positive cells for more than 500 cells, was determined in an increasing order as follows: FH, 3.3 ± 1.8; AFX, 12.2 ± 6.3; and MFH, 21.5 ± 10.2. However, the MIB-1 LI of each case in AFX was considerably scattered, and the MIB-1 LI of AFX and MFH overlapped each other. A DNA analysis revealed that the proliferative index (S + G2 + M fraction) showed no significant correlation with the MIB-1 LI, and an aneuploid pattern was present in only five (42%) of 12 cases of MFH. p53 positivity was detected in 2 (40%) of 5 cases of AFX and 6 (38%) of 16 cases of MFH. Conclusions. Although AFX shows a lower degree in the MIB-1 LI than MFH, the MIB-1 LI shows a limited value in relation to the biologic activity of fibrohistiocytic tumors. Aneuploidy demonstrates a malignant potential in fibrohistiocytic tumors. Cancer 1995;75:1128–34. References 1 Kindblom LG, Jacobsen GK, Jacobsen M. Immunohistochemical investigations of tumors of supposed fibroblastic histiocytic origin. Hum Pathol 1982; 13: 834–40. 2 Eusebi V, Ceccarelli C, Piscioli F, Cristofolini M, Azzopardi JG. Spindle cell tumours of the skin of debatable origin. An immunocytochemical study. J Pathol 1984; 144: 189–99. 3 Kuwano H, Hashimoto H, Enjozi M. Atypical fibroxanthoma distinguishable from spindle cell carcinoma in sarcoma-like skin lesions. A clinicopathologic and immunohistochemical study of 21 cases. Cancer 1985; 55: 172–80. 4 Leong AS-Y, Milios J. Atypical fibroxanthoma of the skin: a clinicopathological and immunohistochemical study and a discussion of its histogenesis. Histopathology 1987; 11: 463–75. 5 Ricci A Jr., Cartun RW, Zakowski MF. Atypical fibroxanthoma. A study of 14 cases emphasizing the presence of Langerhans' histiocytes with implications for differential diagnosis by antibody panels. Am J Surg Pathol 1988; 12: 591–8. 6 Eckert J, Burg G, Braun-Falco O, Schmid U, Gloor F. Immunostaining in atypical fibroxanthoma of the skin. Pathol Res Pract 1988; 184: 27–34. 7 Ma CK, Zarbo Rj, Gown AM. Immunohistochemical characterization of atypical fibroxanthoma and dermatofibrosarcoma protuberans. Am J Clin Pathol 1992; 97: 478–83. 8 Longacre TA, Smoller BR, Rouse RV. Atypical fibroxanthoma. Multiple immunohistologic profiles. Am J Surg Pathol 1993; 17: 1199–209. 9 Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357–63. 10 Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990; 17: 489–503. 11 Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710–5. 12 Sasaki K, Matsumura K, Tsuji T, Shinozaki F, Takahashi M. Relationship between labelling indices of Ki-67 and BrdUrd in human malignant tumors. Cancer 1988; 62: 989–93. 13 Ooe M, Nogita T, Kawashima M. Comparative study of Ki-67 immunostaining and nuclear DNA content in histiofibrous tumors. J Dermatoll 1992; 19: 12–8. 14 Stenfert Kroese MC, Rutgers DH, Wils IS, Van Unnik JAM, Roholl PFM. The relevance of the DNA index and proliferation rate in the grading of benign and malignant soft tissue tumors. Cancer 1990; 65: 1782–8. 15 Ueda T, Aozasa K, Tsujimoto M, Osawa M, Uchida A, Aoki Y, et al. Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer 1989; 63: 1607–11. 16 Schutte B, Reynder MMJ, Bosman FT, Blijham GH. Flow cytometric determination of DNA ploidy level in nuclei isolated from paraffin-embedded tissue. Cytometry 1985; 6: 26–30. 17 Vindeløv LL, Christensen IJ, Nissen NI. A detergent trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983; 3: 323–7. 18 Kallionieme O-P, Punnonen R, Mattila J, Lehtinen M, Koivula T. Prognostic significance of DNA index, multiploidy and S-phase v fraction in ovarian cancer. Cancer 1988; 61: 334–9. 19 Fletcher CDM. Pleomorphic malignant fibrous histiocytoma: fact or fiction? a critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 1992; 16: 213–28. 20 Fletcher CDM. Commentary: malignant fibrous histiocytoma? Histopathology 1987; 11: 433–7. 21 Barbareschi M, Girlando S, Cristofolini P, Cristofolini M, Togni R, Boi S. p53 Expression in basal cell carcinomas. Histopathology 1992; 21: 579–81. 22 Brach DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, et al. A role for sunlight in skin cancer: UV induced pd p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991; 88: 10124–8. Citing Literature Volume75, Issue51 March 1995Pages 1128-1134 ReferencesRelatedInformation